A U.S. District Court judge in Delaware has denied Norwich Pharmaceuticals’ motion to modify the court’s final judgment, which blocks the FDA from approving their 550 mg rifaximin generic until Oct. 2, 2029.
This decision by Judge Richard G. Andrews bolsters his previous ruling that Norwich’s abbreviated new drug application for rifaximin infringed on Bausch Health’s
<p><span>Thank you to the Organising Partners and Patrons for the invitation to speak</span><span> here at City Week on key risks of digital assets.</span></p>
Hockey Memorabilia Maker’s Infringement Lawsuit against Competitor Melts Away - William Grondin (“Grondin” or “Plaintiff”), a creator and seller of hockey memorabilia,.